ZGN-1061

Zafgen presents Phase II data from Type 2 diabetes drug currently on FDA hold

An analyst called the data, on ZGN-1061, encouraging in a relatively small study but added that more preclinical data will be needed to give a clearer picture of the way forward for the drug.

By Alaric DeArment

Pharma

FDA places hold on Zafgen’s metabolic drug, sending shares tumbling

The company's shares were down more than 40 percent in midday trading as the FDA placed a clinical hold on ZGN-1061, the second such hold the company has experienced in three years.

By Alaric DeArment